In this report we examined counts of individuals using trimethoprim-sulfamethoxazole (TMP-SMX) and rates of acute respiratory failure (ARF) during treatment. We assessed indications for TMP-SMX dispensing as well as concurrent diagnoses at the time of ARF diagnoses. We repeated the analyses for four other antibiotics of interest.
The study period included data from January 1, 2000 to December 31, 2019. We distributed this request to 14 Data Partners on May 15, 2020.